Reduction of blood activation in patients receiving aprotinin during cardiopulmonary bypass for coronary artery surgery

ASAIO Journal

Volumn 42, Issue 5, 1996, Pages

  Baufreton, C ^a   Te Velthuis, H ^b   Jansen, P G M ^c   Le Besnerais, P ^a   Wildevuur, C H R ^a   Loisance, D Y ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b CENTRAL LABORATORY   (Netherlands)

^c Centre for Cardiopulmonary Surgery   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; CARDIOVASCULAR SYSTEM; GRAFTS; HEMODYNAMICS; MATHEMATICAL MODELS; REGRESSION ANALYSIS; SURGERY;

APROTININ; BLOOD ACTIVATION; CARDIOPULMONARY BYPASS; CORONARY ARTERY; MULTIVARIATE ANALYSIS;

CARDIOVASCULAR SURGERY;

APROTININ;

ADULT; AGED; BLOOD CLOTTING; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; CORONARY ARTERY BYPASS GRAFT; FEMALE; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE HEMORRHAGE; REVIEW;

EID: 0030250232     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002480-199609000-00023     Document Type: Review

References (25)

1. Edmunds LH: Blood-surface interactions during cardiopulmonary bypass. J Card Surg 8: 404-410, 1993.
2. Hornick P, George A: Blood contact activation: pathophysiological effects and therapeutic approaches. Perfusion 11: 3-19, 1996.
3. Kluft C: Pathomechanisms of defective hemostasis during and after extracorporeal circulation: contact phase activation, in Friedel N, Hetzer R, Royston D (eds), Blood Use in Cardiac Surgery, Darmstadt, Steinkopff Verlag, New-York, Springer Verlag, 1991, pp. 10-15.
4. Chenoweth DE, Cooper SW, Hugli TE, Steward RW, Blackstone EH, Kirklin JW: Complement activation during cardiopulmonary bypass. Evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 304: 497-503, 1981.
5. Butler J, Rocker GM, Westaby S: Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 55: 552-559, 1993.
6. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD: Complement and damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 86: 845-857, 1983.
7. Moore FD, Warner KG, Assousa S, Valeri CR, Khuri SF: The effects of complement activation during cardiopulmonary bypass. Ann Surg 208(1): 95-103, 1988.
8. 2-plasmin-inhibitor complexes during cardiopulmonary bypass. Blood 73: 468-471, 1989.
9. Bidstrup BP, Royston D, Sapsford RN, Taylor KM: Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 97: 364-372, 1989.
10. Van Oeveren W, Jansen NJG, Bidstrup BP, et al: Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 44: 640-645, 1987.
11. Van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur ChRH: Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 99: 788-797, 1990.
12. Tabuchi N, Huet RCG, Sturk A, Eijsman L, Wildevuur ChRH: Aprotinin preserves hemostatis in aspirin treated patients undergoing cardiopulmonary bypass. Ann Thorac Surg 58: 1036-1039, 1994.
13. Murkin JM, Lux J, Shannon NA, et al: Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 107: 554-561, 1994.
14. Wachtfogel YT, Kucich U, Hack CE, et al: Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 106: 1-10, 1993.
15. Nuijens JH, Huijbreghts CCM, Cohen M, et al: Detection of activation of the contact system of coagulation in vitro and in vivo: quantifiication of activated Hageman factor-C1-inhibitor and kallikrein-Cl-inhibitor complexes by specipfic radioimmunoassays. Thromb Haemost 58: 778-785, 1987.
16. Hack CE, Paardekooper J, Eerenberg AJM, et al: A modified competitive inhibition radioimmunoassaynfor the detection of C3a. Use of 125I-C3 instead of 125I-C3a. J Immunol Methods 108: 77-84, 1988.
17. Wolbink GJ, Bollen J, Baars JW, et al: Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods 163: 67-76, 1993.
18. Mollnes TE, Lea T, Froland SS, Harboe M: Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 22: 197-202, 1985.
19. Wachtfogel YT, Kucich U, James HL, et al: Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 72: 1672-1677, 1983.
20. Bachman F, Parise P: Fibrinolysis, in Friedel N, Hetzer R, Royston D (eds), Blood Use in Cardiac Surgery, Darmstadt, Steinkopff Verlag, New-York, Springer Verlag, 1991, pp. 3-9.
21. Tabuchi N, de Haan J, Boonstra PW, van Oeveren W: Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J Thorac Cardiovasc Surg 106: 828-833, 1993.
22. Lu H, Du Buit C, Soria J, et al: Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy. Thromb Haemost 72: 438-443; 1994.
23. Liu B, Tengborn L, Larson G, et al: Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations. Ann Thorac Surg 59: 1534-1540, 1995.
24. Personnet V, Dean D, Bernstein AD: A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart disease. Circulation 79(Suppl 1): I-3-I-12, 1989.
25. Jansen PGM, te Velthuis H, Oudemans-van-straten HM, et al: Perfusion-related factors of endotoxin release during cardiopulmonary bypass. Eur JCardiothorac Surg 8: 125-129, 1994.